A study was conducted to see whether liraglutide helped with improving excessive daytime sleepiness for those with Type II diabetes who were also obese. This included 158 obese adults with a body mass of over 30kg/m2 and Type II diabetes who had begun liraglutide therapy at the start of the study. A significant amount of data was collected, including data from the Epworth Sleeping Scale (ESS), anthropometric parameters, glucose-control, and metabolic parameters. This data was collected at baseline and at both one month and three months after baseline.
The results showed major reductions in ESS score with the study participants at both months 1 and 3 (-1.3±2 p <0.001 and -1.5 ± 3.0 p<-.001, respectively). Significant reductions were also seen after 3 months in body weight, BMI, waist and neck circumferences, HbA1c, mean blood glucose, fasting blood glucose, triglycerides, and total cholesterol levels.
Overall, 3 months of liraglutide treatment proved effective in reducing excessive daytime sleepiness in obese participants with Type II diabetes. More research is required to see if liraglutide could improve other abnormal sleep pattern disorders and obstructive sleep aponea. I am wondering if liraglutide does one day prove to be effective in improving these disorders, would it be able to be indicated for patients without diabetes or obesity but with sleep disorders?
BMC Endocr Disord. 2015 Dec 4;15:78
Obesity is a serious problem in the United States. Obesity increases a person’s risk for a multitude of health problems, including diabetes mellitus type 2. However, it is sometimes extremely difficult for individuals to lose weight through lifestyle changes alone, especially as they get older. In this study, the use of 3.0 mg of liraglutide daily for weight loss was studied to determine whether or not it is efficient and safe.
The study was a placebo-controlled, double-blind trial that lasted 56 weeks. 3731 patients were involved. No participant had type 2 diabetes and every person had a BMI of 30 or more or a BMI of 27 or more and dyslipidemia or hypertension. Each participant received either a daily dose of 3.0 mg liraglutide or a placebo. At the end of the trial the primary end points were change in body weight and percentage of patients that lost at least 5% or 10% of their body weight. The results of the study showed that the group assigned liraglutide lost a mean of 8.4 ± 7.3 kg while the group assigned a placebo lost only 2.8 ± 6.5 kg. Additionally, participants in the liraglutide group 63.2% lost at least 5% of their body weight and 33.1% lost at least 10%. In the placebo group only 27.1% lost at least 5% and 10.6% lost at least 10%. All of the differences between the groups were statistically significant.
I found this study interesting because I was unaware of any prescription medications currently being tested to help weight loss. I believe if a medication can be determined to help weight loss without serious side effects then it should be used to help the country’s obesity problem. However, a medication cannot be the sole technique used. People on the medication should also restrict their diet and exercise regularly. Even if the medication is approved for weight loss, it should only be temporary. Patients need to learn how to maintain a healthy lifestyle so that they can eventually succeed without it and not take the medication permanently.
Pi-Sunyer X, Astrup A, Fujioka K, et al. A Randomized, Controlled Trial of 3.0 Mg of Liraglutide in Weight Management. N Engl J Med. 2015; 373(1): 11-22.